CSA Medical Inc., a pioneering force in the field of advanced interventional therapies, is excited to announce the successful completion of a funding round, securing an impressive $53 million to further advance its innovative RejuvenAir System. This proprietary interventional liquid nitrogen spray cryotherapy system represents a groundbreaking advancement in medical technology, utilizing a unique combination of software-driven dosimetry and specialized catheters to precisely deliver cryogen spray within the airways. The result is a revolutionary method of flash-freezing and destroying damaged cells, allowing for a rejuvenative pattern of healing that has the potential to transform treatment approaches for various respiratory conditions.
The newly acquired funding will be instrumental in accelerating the ongoing clinical investigations of the RejuvenAir System in the United States, alongside facilitating broader market penetration in Europe where the system is already approved. With the backing of this latest investment, CSA Medical aims to enhance its research and development capabilities, ensuring that healthcare providers have access to the most effective and cutting-edge treatment options.
CSA Medical is committed to improving patient outcomes and expanding the horizons of what is possible in respiratory care. As the company gears up for the next phase of its growth, stakeholders and the medical community alike can look forward to the exciting developments on the horizon. For more insight into CSA Medical's technology and clinical trials, please visit www.rejuvenair.com or check out [ClinicalTrials.gov](http://www.clinicaltrials.gov) under the identifiers NCT03893370 and NCT03892694.
